Ro

Introducing Ro’s GLP-1 Supply Tracker – a free, open access tool to help patients and providers find out which medications are available (and where) and which aren’t. https://lnkd.in/en5qTGAa We built this tracker to give patients an easier way to navigate GLP-1 shortages, by: 1️⃣ Clearly showing which GLP-1s are currently in shortage by drug and dose 2️⃣ Making it easy for everyone to crowdsource where and when they find GLP-1 supply or, when they cannot, to submit a shortage report to the FDA 3️⃣ Letting anyone join our “Supply List” that sends real-time alerts when GLP-1 supply is located at a pharmacy near them 4️⃣ Sending automated notifications to patients and providers who sign-up letting them know when a drug’s status changes on the FDA’s list. Our hope is that this tracker will help ease the burden that drug shortages have placed on patients and providers, and increase access to these life-changing treatments.

"Ro is founded on the principle of helping patients get the most effective treatments at the most affordable prices." Ro CEO Zachariah Reitano joined Melissa Lee and the Fast Money team on CNBC to share more about our work with Eli Lilly and Company to give patients access to Zepbound vials through one seamless, end-to-end experience. Watch their discussion here: https://lnkd.in/gnp8YnUc

Today, we're announcing that we're working with Eli Lilly and Company to expand access to Zepbound vials. https://lnkd.in/eRWJRDbe Through a first-of-its-kind integration with LillyDirect, patients can now access the single-dose vials through Ro – offering a seamless obesity care experience bringing together telehealth, lab, and pharmacy services. This direct-to-patient innovation advances our common goal of making it easier for eligible patients to get FDA-approved medicines that can help them achieve their goals.

The stats back it up: Patients in Ro’s Body membership benefit from pairing effective GLP-1 medications with convenient access to high-quality, ongoing obesity care. Our latest research reveals:  ✨ 15.8% average body weight loss after 12 months on GLP-1 treatment. ✨ 80% of patients with metabolic risks significantly improved lab results like cholesterol and triglycerides in a year. This isn’t just about numbers—it’s about helping patients unlock healthier, more fulfilling lives. https://lnkd.in/ebD29Bp6

Today, we’re sharing research highlighting the many ways accessing obesity care through Ro can change lives. Patients come to Ro to live happier, more fulfilled lives: 🌟 80% of patients report increased confidence 🏃♀️ 66% are back to enjoying physical activities they love 👖 94% fit into their old clothes after a year with Ro Check more ways that we’re helping our patients achieve their goals: https://lnkd.in/eXPjmw_2

#OW2024 is underway in San Antonio, TX, and we’re excited to share our latest research. The research sheds light on key issues in obesity medicine today, including: 💡How telehealth can bridge access to weight management care for patients living in rural areas or care deserts. 💡Patients' diverse motivations for weight loss and their relationship to quality of life. 💡The role technology plays in monitoring and managing side effects among patients treated with GLP-1s. Follow the link below to learn more about what we're presenting at ObesityWeek: https://lnkd.in/eJnAFMbV #obesitycare #research #insights

Ro turns seven today! Cheers to an incredible seven years of making healthcare easier and more effective for patients, while empowering them to achieve their health goals. 🎉 In celebration, we invited a few Ro Body members to share their stories with Ro'ers. Hearing their experiences reminded us of our purpose: helping patients live happier, more fulfilling lives. Swipe through to see just a glimpse of the powerful stories our patients shared with us!

"It's a win for us when [patients] get access to their medication at an affordable price...We hope that competition leads to the prices coming down." Ro CEO Zachariah Reitano joined Yahoo Finance’s Market Domination with Anjalee Khemlani to discuss the importance of accessible obesity treatments and the rapidly evolving GLP-1 landscape. Watch the full interview here: https://lnkd.in/enygVmWb

"Cost, quality, and convenience – and not having to trade off on any of those is why patients come to us." Ro CEO Zachariah Reitano joined Dan Primack at #AxiosBFD this week to talk about the incredible potential of GLP-1s in healthcare and share more about Ro's journey to helping millions of patients achieve their goals. You can watch their talk here: https://lnkd.in/dSe_sVGD 

We’re excited to see our patient, Danielle, featured in Verywell Mind, where she shares her experience with food noise. https://lnkd.in/ekFRsrxd Since beginning GLP-1 treatment with Ro, Danielle has found relief from food noise, allowing her to focus on what matters most: quality time with her family. Now, she’s enjoying moments like coaching her son’s basketball team and fun date nights with her husband.